Base Editing Market by Product (Platform, Reagents & Kits, Plasmids), Service (gRNA Design, Cell Line Engineering), Type, Targeted base (Cytosine, Adenine), Application (Drug Discovery, Agriculture, Veterinary), and Region - Global Forecast to 2028

Base Editing Market by Product (Platform, Reagents & Kits, Plasmids), Service (gRNA Design, Cell Line Engineering), Type, Targeted base (Cytosine, Adenine), Application (Drug Discovery, Agriculture, Veterinary), and Region - Global Forecast to 2028

The Base editing market is projected to reach USD 549 million by 2028 from an estimated USD 270 million in 2023, at a CAGR of 15.2% during the forecast period. The growth of this market can be attributed to the growing demand for novel genetic therapies and personalized medicine, coupled with the development of newly engineered molecules. That is expected to treat rare genetic disorders and increase the yield of genetically modified crops, propelling the growth of the overall market. The increasing recognition of the role of genetic mutations in various diseases has fueled the demand for precise gene editing technologies. Base editing's ability to correct disease-causing mutations contributes to its relevance in addressing genetic disorders.

“The platform segment accounted for the largest share by product & services in 2022.”

In 2022, the platform segment accounted for the largest share of product & service in the global base editing market. The factors like base editing platforms offer end-to-end solutions that cover the entire workflow from designing guide RNAs to delivering base editors into target cells. This comprehensive approach simplifies the experimentation process for researchers and may contribute to the popularity of platforms over individual components.

“The North America region continued to dominate the base editing market during the forecast period of 2023-2028.”

North America dominated the global base editing market in 2022. The demand for advanced gene editing technologies is high in North America due to the region's focus on personalized medicine, precision therapeutics, and the treatment of genetic disorders. As a result, companies in the region are more inclined to adopt and invest in base editing technologies. Moreover, North America has a well-educated and skilled workforce in the fields of molecular biology, genetics, and biotechnology. The availability of a talented workforce contributes to the region's ability to lead in the development and application of advanced genomic editing technologies. These factors are contributing to the growth of the North American base editing market.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

Danaher Corporation (US)

Merck KGaA (Germany)

Revvity (US)

Maravai LifeSciences (US)

GenScript (China)

Beam Therapeutics (US)

Intellia Therapeutics, Inc. (US)

Cellectis (France)

ElevateBio (US)

Creative Biogene (US)

Bio Palette Co., Ltd (Japan)

Addgene (US)

Synthego (US)

EdiGene, Inc. (China)

Shape TX (US)

Pairwise (US)

ProQR Therapeutics (Netherlands)

QI-Biodesign (China)

KromaTiD, Inc. (US)

GenKOre. (South Korea).

Research Coverage:

This research report categorizes the base editing market by product & service (service (gRNA design, cell line engineering, and other services) product (platforms, kits & reagents, plasmids, and base editing libraries), by targeted base (cytosine base editor, adenine base editor), by type (DNA base editing, RNA base editing), by application (drug discovery & development, agriculture, and veterinary), by end user (pharmaceutical & biotechnological companies, academic & research institutes, and contract research organizations).

The report's scope encompasses detailed information regarding major influencing factors such as drivers, trends, challenges, and opportunities shaping the growth of the base editing market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers recent developments, including new product launches, mergers, and acquisitions, in the base editing market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall base editing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (the rising government funding and growth of genomics studies, increased applications of genomics in pharmaceuticals, rising prevalence of rare diseases, and increased precision & reduced off-target effects with base editing), restraints (ethical & safety concerns), opportunities (Increasing pipeline of gene therapy & regulatory approvals), and challenges (Challenges associated with off-target effects) influencing the growth of the market.

Product Development/Innovation: Detailed insights on newly launched products in the base editing market

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the base editing market

Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Revvity (US), Maravai LifeSciences (US), GenScript (China), Beam Therapeutics (US), Intellia Therapeutics, Inc. (US), Cellectis (France), ElevateBio (US), Creative Biogene (US), Bio Palette Co., Ltd (Japan), Addgene (US), Synthego (US), EdiGene, Inc. (China), Shape TX (US), Pairwise (US), ProQR Therapeutics (Netherlands), QI-Biodesign (China), KromaTiD, Inc. (US), GenKOre. (South Korea) and among others in the market.